• Amgen Inc. recently reported second-quarter 2026 results showing revenue of US$10,054 million and net income of US$2,375 million, and issued full-year 2026 guidance for total revenue of US$38.20 billion to US$39.40 billion and GAAP EPS of US$15.80 to US$17.08 with a tax rate of 14.5% to 16.0%.
• These results, alongside stronger earnings per share and updated full-year targets, highlight how Amgen’s existing portfolio is currently supporting its long-term pipeline-driven growth story.
• We’ll now explore how Amgen’s raised full-year 2026 earnings guidance interacts with its existing investment narrative and risk‑reward profile.

The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Amgen Investment Narrative Recap

To own Amgen, you need to believe its established drugs and growing pipeline can together support steady revenue and earnings, even as pricing and biosimilar pressures build. The latest second quarter beat and higher 2026 guidance support this narrative in the near term, but do not remove the key risk that biosimilar competition and policy-driven price cuts could eventually weigh on margins and cash generation.

The most relevant update here is Amgen’s raised 2026 outlook to US$38.20 billion to US$39.40 billion in revenue and GAAP EPS of US$15.80 to US$17.08, up from earlier guidance. This stronger full year framework, backed by first half revenue of US$18,672 million and higher net income, reinforces the current earnings base behind Amgen’s pipeline story, even as long term risks around drug pricing and competition remain in focus.

Yet even with this stronger 2026 guidance, investors should still be aware that pricing reform and biosimilar pressure could...

Amgen's narrative projects $41.5 billion revenue and $10.3 billion earnings by 2029. This requires 2.9% yearly revenue growth and an earnings increase of about $1.6 billion from $8.7 billion today.

Uncover how Amgen's forecasts yield a $371.93 fair value, a 11% downside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were assuming roughly flat revenue near US$37.2 billion and only modest profit growth, so their more cautious view could shift meaningfully after this guidance beat, and it is worth weighing that against your own expectations.

Explore 5 other fair value estimates on Amgen - why the stock might be worth 14% less than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Amgen research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Amgen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amgen's overall financial health at a glance.

Ready For A Different Approach?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.
• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.